Antioxidant activity and spectroscopic investigations on the interaction of methimazol-Cu(II) complex with BSA.

E. G. FERRER; NORA M. URQUIZA; SILVIA G. MANCA; LEZAMA, L.; ROJO, T.; LUCIANA NASO; P. A. M. W ILLIAMS

Tucson, Arizona

Conferencia; BioMetals Conference 2010; 2010

Several copper complexes have been shown to possess anticancer, anticarcinogenic, and antimutagenic effects both in vitro and in vivo. In particular, in tumoral cells, the SOD activity is lower than in normal cells and as a consequence a variety of copper complexes presenting SOD-like activity were examined for anticancer treatments. Drastic lowering of the SOD activity in erythrocytes has also been reported during methimazole administration in patients with Grave's disease [1]. Considering the potential SOD mimetic activity of many copper(II) complexes, and that methimazole in combination with anticancer prodrug cyclophosphamide demonstrated antitumoral effects [2], the antioxidant properties of bioactive methimazole-copper(II) complex [3] have been tested. Methimazole do not show SOD activity while [Cu(MeimzH)2(NO3)2].0.5H2O exhibited a strong superoxide radical scavenging activity (IC50=2.95x10-6M).  On the other hand, Serum albumin is the major transport protein, and the overall distribution, metabolism and efficacy of many drugs in the body are correlated with their affinities towards this protein. For this reason, we have also investigated the mechanism of binding of our bioactive compound with BSA protein by EPR, UV-vis, Raman and Fluorescence spectroscopies.